Form 4: Artelo Biosciences Director Acquires Convertible Promissory Note

Connie Matsui, a director at Artelo Biosciences, acquired a convertible promissory note for $140,000 on May 1, 2025, which may be converted into common stock or warrants.

Summary

• On May 1, 2025, Artelo Biosciences entered into a Subscription Agreement with director Connie Matsui.
• Matsui acquired a convertible note for $140,000.
• The note accrues interest at 12% per annum, increasing to 20% upon an Event of Default.
• The note matures on October 28, 2025.
• At maturity, Matsui has the option to convert the unpaid principal and accrued interest into common stock at a conversion price determined by dividing the outstanding amount by $1.29, but not less than $1.04 per share.
• If Matsui doesn't elect voluntary conversion, the remaining amount will be automatically converted into a warrant to purchase common stock at $0.125 per share, with an exercise price equal to the Minimum Price of $1.04.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's investment is a positive signal, but the terms of the note, including the potential for increased interest rates upon default, introduce some risk.

Positives

• The investment by a director signals confidence in the company's prospects.
• The convertible note provides Artelo Biosciences with additional capital.

Risks

• The 20% interest rate upon an Event of Default could strain the company's finances if such an event occurs.
• The conversion of the note into common stock could dilute existing shareholders' equity.

Future Outlook

The document outlines the terms of a convertible note agreement, indicating a potential future conversion into common stock or warrants, depending on the director's decision at the maturity date.

Industry Context

Convertible notes are a common financing tool for small-cap companies like Artelo Biosciences, allowing them to raise capital without immediately diluting existing shareholders. The terms of the note, including the interest rate and conversion price, are typical for this type of financing.

Comparison to Industry Standards

• Convertible notes are frequently used by biotechnology companies of similar size to Artelo Biosciences to fund research and development.
• The interest rate of 12% is within the typical range for convertible notes issued by companies with similar risk profiles.
• The conversion price represents a premium over the current market price, which is standard practice to incentivize investment.

Related Party Transactions

• The issuance of the convertible note to Connie Matsui, a director of Artelo Biosciences, is a related party transaction.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• The company's financial stability could be affected by the interest payments on the note, especially if an Event of Default occurs.

Next Steps

• The director will decide whether to convert the note into common stock at maturity.
• The company will need to manage its finances to avoid an Event of Default and the associated higher interest rate.

Key Dates

Keywords

convertible note, Artelo Biosciences, director, Connie Matsui, financing, common stock, warrant